Resource Library

Antibody-drug conjugates (ADCs) are reshaping cancer care but the summit is still ahead. Despite landmark approvals in breast and urothelial cancers, too many ADCs still stumble on toxicity, limited efficacy or trial design hurdles. The next generation demands smarter payloads, adaptive trial strategies and modular platforms that can scale across tumor types.

In this white paper, Syneos Health experts explore:

•  Why progress has slowed: From antigen limitations and resistance mechanisms to linker instability and suboptimal trial designs.

•  Where the opportunities lie: With novel payload classes, smarter linkers, rational combinations, and innovative formats that expand the target universe.

•  What it takes to reach ADC 2.0: Including adaptive trial strategies, platform-driven development, and scalable models that echo the speed and flexibility of mRNA innovation.

Download now to see where ADC innovation is headed and how oncology teams can position for success in the decade ahead.